title: Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.
abstract: A needlestick injury occurred during an animal experiment in the biosafety level 4 laboratory in Hamburg, Germany, in March 2009. The syringe contained Zaire ebolavirus (ZEBOV) mixed with Freund's adjuvant. Neither an approved treatment nor a postexposure prophylaxis (PEP) exists for Ebola hemorrhagic fever. Following a risk-benefit assessment, it was recommended the exposed person take an experimental vaccine that had shown PEP efficacy in ZEBOV-infected nonhuman primates (NHPs) [12]. The vaccine, which had not been used previously in humans, was a live-attenuated recombinant vesicular stomatitis virus (recVSV) expressing the glycoprotein of ZEBOV. A single dose of 5 × 10(7) plaque-forming units was injected 48 hours after the accident. The vaccinee developed fever 12 hours later and recVSV viremia was detectable by polymerase chain reaction (PCR) for 2 days. Otherwise, the person remained healthy, and ZEBOV RNA, except for the glycoprotein gene expressed in the vaccine, was never detected in serum and peripheral blood mononuclear cells during the 3-week observation period.
authors: Department of Virology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany. guenther@bni.uni-hamburg.de
authors: Stephan
authors: S
authors: Günther
authors: Heinz
authors: H
authors: Feldmann
authors: Thomas W
authors: TW
authors: Geisbert
authors: Lisa E
authors: LE
authors: Hensley
authors: Pierre E
authors: PE
authors: Rollin
authors: Stuart T
authors: ST
authors: Nichol
authors: Ute
authors: U
authors: Ströher
authors: Harvey
authors: H
authors: Artsob
authors: Clarence J
authors: CJ
authors: Peters
authors: Thomas G
authors: TG
authors: Ksiazek
authors: Stephan
authors: S
authors: Becker
authors: Jan
authors: J
authors: ter Meulen
authors: Stephan
authors: S
authors: Olschläger
authors: Jonas
authors: J
authors: Schmidt-Chanasit
authors: Hinrich
authors: H
authors: Sudeck
authors: Gerd D
authors: GD
authors: Burchard
authors: Stefan
authors: S
authors: Schmiedel
mesh_terms: D000818:Animals; D003264:Containment of Biohazards; D046129:Ebola Vaccines / Q000008:administration & dosage / Q000592:standards; D029043:Ebolavirus; D005858:Germany; D019142:Hemorrhagic Fever, Ebola / Q000517:prevention & control*; D006801:Humans; D007757:Laboratory Infection / Q000517:prevention & control*; D051379:Mice; D016602:Needlestick Injuries / Q000821:virology; D016273:Occupational Exposure; D056990:Post-Exposure Prophylaxis / Q000379:methods*; D012367:RNA, Viral / Q000097:blood; D012108:Research Personnel; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA / Q000276:immunology; D018116:Vesiculovirus / Q000235:genetics; D014766:Viremia
chemical_list: D046129:Ebola Vaccines; D012367:RNA, Viral; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA